20:44 , May 22, 2019 |  BC Extra  |  Company News

May 22 Company Quick Takes: Lilly adds warning to Verzenio's Japanese label; plus Janssen, a pair of China approvals and more

Lung disease warning for Lilly breast cancer drug in Japan  Eli Lilly and Co. (NYSE:LLY) told BioCentury it has updated the Japanese label of breast cancer drug Verzenio abemaciclib to include a warning for interstitial...
00:27 , Jan 30, 2019 |  BC Extra  |  Company News

Amgen's guidance comes up short, but migraine drug sales show promise

Amgen Inc. (NASDAQ:AMGN) reported 4Q18 and 2018 earnings that beat consensus estimates on Tuesday but the bellwether’s 2019 guidance fell shy of analyst expectations. The company said it expects 2019 non-GAAP EPS of $13.10-$14.30, below...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
04:43 , Dec 15, 2018 |  BioCentury  |  Product Development

O’Day’s expansive task at Gilead

A fresh executive team and a track record of building deep portfolios could allow incoming Gilead Sciences Inc. chairman and CEO Daniel O’Day to do what his predecessors couldn’t: make Gilead a leader outside of...
17:56 , Oct 25, 2018 |  BC Extra  |  Politics & Policy

Trump administration to peg Part B payments to international pricing

The new Trump administration proposal for Medicare Part B could dramatically decrease revenues for companies that are heavily dependent on those sales. Announced just two weeks before Election Day, the proposed changes to Medicare Part...
17:49 , Sep 7, 2018 |  BC Week In Review  |  Financial News

Seidenberg, Harper launch Westlake with $320M inaugural fund

Kleiner Perkins’ Beth Seidenberg launched a life science investment firm, dubbed Westlake Village BioPartners, with $320 million in committed capital for its first fund. Sean Harper, EVP and head of R&D at Amgen Inc. (NASDAQ:AMGN),...
23:30 , Sep 5, 2018 |  BC Extra  |  Financial News

Seidenberg, Harper launch Westlake with $320M inaugural fund

Kleiner Perkins’ Beth Seidenberg launched a life science investment firm Wednesday, dubbed Westlake Village BioPartners, with $320 million in committed capital for its first fund. Sean Harper, EVP and head of R&D at Amgen Inc....
23:56 , Jul 26, 2018 |  BC Extra  |  Company News

Reese succeeding Harper as Amgen EVP of R&D

Amgen Inc. (NASDAQ:AMGN) said EVP of R&D Sean Harper will retire and be succeeded by SVP of Translational Sciences and Oncology David Reese. The company also reported 2Q18 earnings on Thursday after market hours that...
21:30 , Jul 24, 2018 |  BC Innovations  |  Translation in Brief

Interaction analysis

In a collaboration with Merck & Co. Inc. (NYSE:MRK) and SomaLogic Inc., University of Cambridge researchers have identified associations and causal relationships between thousands of genetic variants, plasma proteins and disease states, which could reveal...
20:50 , Apr 6, 2018 |  BC Week In Review  |  Clinical News

EC approves Xgeva for MM patients

Amgen Inc. (NASDAQ:AMGN) said the European Commission approved a label expansion for Xgeva denosumab to include the prevention of skeletal-related events in patients with multiple myeloma (MM). FDA approved Xgeva in the same indication in...